Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trialAxel Hauschild, Paul B. Chapman, Wilson H. Miller et al.|The Lancet|2012Cited by 3k
Randomized, Multinational, Phase III Study of Docetaxel Plus Platinum Combinations Versus Vinorelbine Plus Cisplatin for Advanced Non–Small-Cell Lung Cancer: The TAX 326 Study GroupFrank V. Fossella, Chandra P. Belani, Jose R. Pereira et al.|Journal of Clinical Oncology|2003Cited by 943
Long-term outcomes in patients with BRAF V600-mutant metastatic melanoma receiving dabrafenib monotherapy: Analysis from phase 2 and 3 clinical trialsAxel Hauschild, Paul B. Chapman, Paolo A. Ascierto et al.|European Journal of Cancer|2020Cited by 69
Updated 5-y landmark analyses of phase 2 (BREAK-2) and phase 3 (BREAK-3) studies evaluating dabrafenib monotherapy in patients with <i>BRAF</i> V600–mutant melanoma.Paul B. Chapman, Axel Hauschild, Paolo A. Ascierto et al.|Journal of Clinical Oncology|2017Cited by 6